GHRS

SEC filing GHRS Reports Phase 2b Trial Results: GH001 Shows -2.00 Cohen's d Reduction in MADRS Anhedonia Factor Scores vs Placebo at Day 8

12d ago

News GH Research GAAP EPS of -$0.31

19d ago

SEC filing GHRS Posts $18.97M Q1 Loss, $0.31 EPS, $142M Cash Boost from $150M Share Issue

19d ago

News GH Research prices $117.5M share offering

34d ago

News Cybin stands out as the most undervalued psychedelic stock as Trump signs on faster PTSD research

43d ago

News Psychedelic stocks rally after Trump orders faster PTSD research; Compass Pathways, Atai lead gains

43d ago

SEC filing GHRS Reports $280.7M Cash, $48.3M Net Loss, +$38.8M R&D, Phase 2b MADRS -15.5, 57.5% Remission, FDA Alignment Target 2026

89d ago

News GH Research surges as FDA lifts clinical hold on depression therapy

148d ago

News Stock Market Today: S&P 500, Nasdaq Futures Rise, WTI Fluctuates Following US Strike On Venezuela— GH Research, Vertiv Holdings, Nukkleus In Focus

148d ago

News GH Research surges on upcoming late-stage trial update

150d ago

News GH Research Announces Novel Therapies Symposium Presentation and Posters at the 2025 ECNP Congress

153d ago

Scanner Unusual volume (z=4.1)

160d ago

Scanner Unusual volume (z=4.3)

161d ago

Scanner Unusual volume (z=4.3)

163d ago

Scanner Unusual volume (z=4.3)

164d ago